Become a Member

Get access to more than 30 brands, premium video, exclusive content, events, mapping, and more.

Already have an account? Sign In

Become a Member

Get access to more than 30 brands, premium video, exclusive content, events, mapping, and more.

Already have an account? Sign In

Brands

Road

Fabio Taborre suspended for adverse analytical finding of EPO-stimulating drug

Androni Giocattoli-Sidermec faces suspension for second failed test in 2015

Don't miss a moment from Paris-Roubaix and Unbound Gravel, to the Giro d’Italia, Tour de France, Vuelta a España, and everything in between when you join Outside+.

The UCI has notified Fabio Taborre (Androni Giocattoli-Sidermec) of an adverse analytical finding of FG-4592, a prohibited substance that stimulates the endogenous production of EPO, in a sample collected during an out-of-competition test on June 16, 2015.

Taborre has the right to request and attend the analysis of the B sample, but has been provisionally suspended until the adjudication of the matter.

Taborre’s failed test constitutes the second adverse analytical finding for an Androni Giocattoli-Sidermec rider since the beginning of 2015—Davide Appollonio was suspended for EPO in June. In accordance with new UCI rules, the team therefore faces a suspension of between 15 and 45 days. The UCI will refer the matter to its Disciplinary Commission, which will render a decision in the upcoming days.